Wilmington Savings Fund Society FSB Lowers Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Wilmington Savings Fund Society FSB trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 30.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 209 shares of the medical research company’s stock after selling 91 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Charles River Laboratories International were worth $39,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CRL. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International during the third quarter worth about $32,000. Versant Capital Management Inc grew its holdings in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. increased its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $56,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $153.20 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a fifty day moving average price of $177.23 and a two-hundred day moving average price of $191.71. The company has a market cap of $7.83 billion, a PE ratio of 19.17, a P/E/G ratio of 6.47 and a beta of 1.37.

Analyst Ratings Changes

A number of research firms have recently issued reports on CRL. The Goldman Sachs Group dropped their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Evercore ISI boosted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Finally, TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).